Table 2 Node-splitting analysis of inconsistency within network meta-analysis.
comparison | p-value | OR (95%CrI) |
|---|---|---|
Myocardial infarction | ||
DPP-4 inhibitors versus GLP-1 agonists | ||
direct | 0.71125 | 0.37 (−0.79, 1.6) |
indirect | 0.099 (−0.34, 0.79) | |
network | 0.12 (−0.27, 0.75) | |
DPP-4 inhibitors versus Placebo | ||
direct | 0.41375 | 0.0016 (−0.35, 0.33) |
indirect | 0.39 (−0.54, 1.4) | |
network | 0.014 (−0.26, 0.38) | |
DPP-4 inhibitors versus Sulfonylureas | ||
direct | 0.53125 | 0.98 (0.38, 1.7) |
indirect | 0.59 (−0.42, 1.7) | |
network | 0.86 (0.30, 1.4) | |
GLP-1 agonists versus Placebo | ||
direct | 0.38375 | −0.037 (−0.61, 0.52) |
indirect | −0.43 (−1.4, 0.41) | |
network | −0.10 (−0.66, 0.26) | |
GLP-1 agonists versus Sulfonylureas | ||
direct | 0.5225 | 0.49 (−0.45, 1.4) |
indirect | 0.87 (0.024, 1.7) | |
network | 0.73 (0.072, 1.3) | |
Angina | ||
DPP-4 inhibitors versus GLP-1 agonists | ||
direct | 0.43125 | −0.17 (−2., 1.7) |
indirect | 0.77 (−0.80, 3.1) | |
network | 0.37 (−0.83, 1.6) | |
DPP-4 inhibitors versus Sulfonylureas | ||
direct | 0.495 | 0.056 (−0.59, 0.80) |
indirect | −0.83 (−3.5, 1.6) | |
network | 0.050 (−0.65, 0.67) | |
GLP-1 agonists versus Sulfonylureas | ||
direct | 0.50125 | −0.68 (−2.6, 0.75) |
indirect | 0.18 (−1.7, 2.3) | |
network | −0.29 (−1.7, 0.83) | |
Coronary arterial diseases | ||
DPP-4 inhibitors versus GLP-1 agonists | ||
direct | 0.02875 | 0.78 (−0.85, 2.8) |
indirect | −2.2 (−4.8, −0.28) | |
network | −0.65 (−1.9, 0.60) | |
DPP-4 inhibitors versus Sulfonylureas | ||
direct | 0.02 | −0.70 (−2., 0.24) |
indirect | 2.5 (−0.036, 5.7) | |
network | −0.34 (−1.3, 0.56) | |
GLP-1 agonists versus Sulfonylureas | ||
direct | 0.015 | 1.6 (−0.11, 3.9) |
indirect | −1.5 (−3.9, 0.36) | |
network | 0.28 (−1.0, 1.5) | |
